This is based on demonstrations that mutations in PI3K are more prevalent in TNBC than in other breast cancers (Koboldt et al., 2012), as well as on the activation of the mTOR pathway and its correlation with poor prognosis (Pelicano et al., 2014). The gene discussed is MTOR; the disease is breast cancer.